Glusod

Glusod is an oral medication whose active ingredient is empagliflozin, a sodium‑glucose co‑transporter 2 (SGLT2) inhibitor marketed in the European Union. It is supplied as a prescription‑only product and is used in the management of type 2 diabetes mellitus. The drug works by reducing renal glucose reabsorption, leading to increased urinary glucose excretion and modest reductions in blood glucose levels. It is available only with a healthcare provider’s prescription.

Glusod (empagliflozin) is indicated for adults with type 2 diabetes mellitus as part of a comprehensive glycemic control plan.

- Adjunct to diet and exercise when metformin alone does not achieve target glycaemic levels. - Combination therapy with other oral antidiabetic agents such as DPP‑4 inhibitors or sulfonylureas. - May be considered in patients with established cardiovascular disease to provide additional risk reduction. - Used when renal function is adequate (eGFR ≥45 mL/min/1.73 m²) as per prescribing information. - Prescribed in fixed‑dose combinations that include empagliflozin and other glucose‑lowering drugs.

The safety profile of empagliflozin includes a range of observed adverse events that are generally categorized by frequency.

Common: - Increased urinary frequency or volume. - Genital mycotic infections (e.g., yeast infections). - Mild dehydration or thirst. - Lower limb edema.

Serious: - Ketoacidosis (euglycemic diabetic ketoacidosis). - Acute kidney injury. - Severe hypersensitivity reactions such as Stevens‑Johnson syndrome.

Before initiating Glusod, clinicians should evaluate several clinical factors to minimise risk and ensure appropriate use.

- Assess renal function; avoid use in patients with severely reduced eGFR. - Monitor for signs of volume depletion, especially in the elderly or those on diuretics. - Caution in patients with a history of genital or urinary tract infections. - Evaluate cardiovascular status; empagliflozin has demonstrated benefit but may require dose adjustment in heart failure. - Review concomitant medications that affect glucose levels to prevent hypoglycaemia. - Consider pregnancy and lactation status; safety data are limited.

Empagliflozin can interact with other medicines, altering its effectiveness or increasing the risk of adverse effects.

Avoid: - Concurrent use of insulin or sulfonylureas without dose adjustment, which may increase hypoglycaemia risk. - Combination with strong diuretics that may exacerbate dehydration or hypotension.

Use with caution: - Co‑administration with renin‑angiotensin‑system blockers (ACE inhibitors, ARBs) requiring renal function monitoring. - Use alongside other SGLT2 inhibitors is not recommended. - NSAIDs or other nephrotoxic agents may increase risk of kidney injury. - Rifampin or other CYP3A4 inducers may reduce empagliflozin exposure.